Using machine learning on tissue from 84 Alzheimer's disease cases, researchers have mapped six distinct amyloid-beta plaque ...
Listen below or download the episode. Find Sharp Waves episodes on Spotify, Apple Podcasts, Google Podcasts, Amazon Music, iHeart Radio, and Stitcher. Sixty percent of patients with dementia on ...
With amyloid immunotherapy in clinical use, scientists need to find better ways to identify the patients most at risk of developing ARIA (see part 16 of this series). One of the biggest danger signs, ...
Please provide your email address to receive an email when new articles are posted on . Cerebral amyloid angiopathy was associated with a higher risk for isolated nontraumatic subdural hemorrhage in ...
Evidence of iatrogenic beta-amyloid transmission was identified in two patients who developed early-onset cerebral amyloid angiopathy decades after undergoing pediatric cardiac surgery. The findings ...
A professor of pharmaceutical and biomedical sciences at the University of Rhode Island’s (URI) College of Pharmacy received a $1.5 million grant to research cerebral amyloid angiopathy (CAA), a ...
Cerebral amyloid angiopathy (CAA) denotes the deposition of amyloid-β peptides within the walls of leptomeningeal and cortical blood vessels. It frequently co-occurs with Alzheimer’s disease and other ...
Cerebral amyloid angiopathy (CAA) is a condition where protein (called amyloid) builds up in the brain, making blood vessels weak. People with CAA are four times more likely to develop dementia within ...
A $1.5M grant has been awarded to William Van Nostrand, co-executive director of the University of Rhode Island's George & Anne Ryan Institute for Neuroscience and professor of pharmaceutical and ...
A PAPER PUBLISHED in this month’s Annals of Neurology, by Gargi Banerjee and David Werring of University College, London, adds to evidence that prion diseases are more widespread and varied than had ...
CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today positive interim results from the ...
As new Alzheimer's drugs move from clinical trials into everyday care, families are asking whether these treatments are safe, how long patients can stay on them and whether they truly slow the disease ...